2019年抗肿瘤新药研发热点回眸

doi:10.3981/j.issn.1000-7857.2020.01.006

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (663 KB) HTML^new
输出: BibTeX | EndNote (RIS)

摘要恶性肿瘤是严重威胁人们健康最主要的慢性非传染性疾病，因此抗肿瘤新药研发成为新药研发的重点领域。近年来随着国家政策扶持和经济社会的持续发展，中国自主研发抗肿瘤新药的能力不断提高。2019年，一些新的国产抗肿瘤新药上市并开始临床应用，给患者提供了更多的治疗选择。本文从生物类似药、免疫治疗药物、靶向药物及抗血管生成药物等方面盘点了2019年上市的部分抗肿瘤新药的研究成果。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	石远凯
	孙燕

关键词 ：肿瘤, 内科治疗, 抗肿瘤新药

Abstract：The research and development of new anti-tumor drugs is the key field of new drug research and development. In recent years, with the support of national policies and the sustainable development of economy and society, China's ability to independently develop new anti-tumor drugs has been continuously improved. In 2019, some new domestic anti-tumor drugs were used clinically, providing more treatment options for patients. In this paper, we review the research results of some new antitumor drugs launched in 2019 market.

Key words： tumour internal medicine treatment new anti-tumor drugs

收稿日期: 2020-01-02

通讯作者: 孙燕(通信作者),中国工程院院士,研究方向为临床肿瘤学,电子信箱:suny@csco.org.cn E-mail: suny@csco.org.cn

作者简介: 石远凯,教授,研究方向为肿瘤内科和抗肿瘤药物临床,电子信箱:syuankai@cicams.ac.cn

引用本文:

石远凯, 孙燕. 2019年抗肿瘤新药研发热点回眸[J]. 科技导报, 2020, 38(1): 77-81.
SHI Yuankai, SUN Yan. Hotspots of new antitumor drugs in 2019. Science & Technology Review, 2020, 38(1): 77-81.

链接本文:

http://www.kjdb.org/CN/10.3981/j.issn.1000-7857.2020.01.006 或 http://www.kjdb.org/CN/Y2020/V38/I1/77

[1] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1):19-28.
[2] 石远凯, 孙燕. 中国原研抗肿瘤新药物的临床试验[J]. 中华肿瘤杂志, 2019, 41(1):68-72.
[3] 姜时雨, 石远凯. 生物类似药在肿瘤领域中的发展现状[J]. 中华肿瘤杂志, 2017, 39(10):721-725.
[4] Shi Y. HLX01, a China-manufactured proposed rituximab biosimilar, matches equivalence of mabthera in treatment for CD20-positive diffuse large b-cell nonhodgkin's lymphoma[C]//In ESMO-ASIA, 2018. Singapore:China Medical Tribune, 2018.
[5] Han B. Efficacy and safety of QL1101 and avastin respectively combined with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer[EB/OL].[2019-12-27]. https://clinicaltrials.gov/ct2/show/NCT03169335.
[6] Song Y, Gao Q, Zhang H, et al. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab:results of a phase 2, single-arm, multicenter study[J]. Leukemia, 2019. doi:10.1038/s41375-019-0545-2.
[7] Antonia S J, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in stage III non-small-cell lung cancer[J]. The New England Journal of Medicine, 2017, 377(20):1919-1929.
[8] Gandhi L, Rodriguez-Abreu D, Gadgeel S et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. The New England Journal of Medicine, 2018, 378(22):2078-2092.
[9] Paz-Ares L, Luft A, Vicente D et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. The New England Journal of Medicine, 2018, 379(21):2040-2051.
[10] Mok T S K, Wu YL, Kudaba I et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042):A randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019, 393(10183):1819-1830.
[11] Wu Y L, Cheng Y, Zhou X et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFRmutation-positive non-small-cell lung cancer (ARCHER 1050):A randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2017, 18(11):1454-1466.
[12] Cheng Y. Anlotinib as third-line or further-line treatment in relapsed SCLC:A multicentral, randomized, double-blind phase 2 trial[C]//In World Conference on Lung Cancer (WCLC), 2018. Toronto:Journal of Thoracic Oncology, doi:10.1016/j.jtho.2018.08.308.
[13] Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma[J]. Clinical Cancer Research, 2018, 24(21):5233-5238.